Suppr超能文献

相似文献

1
Fatty Liver Disease: Diagnosis and Stratification.
Annu Rev Med. 2022 Jan 27;73:529-544. doi: 10.1146/annurev-med-042220-020407. Epub 2021 Nov 22.
2
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
3
Liver transplantation and non-alcoholic fatty liver disease.
World J Gastroenterol. 2014 Nov 14;20(42):15532-8. doi: 10.3748/wjg.v20.i42.15532.
4
Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.
Dig Dis Sci. 2024 Feb;69(2):370-383. doi: 10.1007/s10620-023-08186-8. Epub 2023 Dec 7.
5
Approach to the Patient With Nonalcoholic Fatty Liver Disease.
J Clin Endocrinol Metab. 2023 Jan 17;108(2):483-495. doi: 10.1210/clinem/dgac624.
6
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
9
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
10
Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Semin Liver Dis. 2015 Aug;35(3):221-35. doi: 10.1055/s-0035-1562943. Epub 2015 Sep 17.

引用本文的文献

5
Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease.
Front Pharmacol. 2025 Jul 14;16:1611400. doi: 10.3389/fphar.2025.1611400. eCollection 2025.
7
Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease.
Front Endocrinol (Lausanne). 2025 Jul 4;16:1600559. doi: 10.3389/fendo.2025.1600559. eCollection 2025.
9
Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies.
Int J Hepatol. 2025 Jun 23;2025:5580454. doi: 10.1155/ijh/5580454. eCollection 2025.
10
Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease.
Diagnostics (Basel). 2025 May 10;15(10):1208. doi: 10.3390/diagnostics15101208.

本文引用的文献

1
Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease.
Curr Hepatol Rep. 2019 Dec;18(4):455-472. doi: 10.1007/s11901-019-00499-5. Epub 2019 Nov 15.
3
Frailty and Sarcopenia in Patients Pre- and Post-Liver Transplant.
Clin Liver Dis. 2021 Feb;25(1):35-51. doi: 10.1016/j.cld.2020.08.004. Epub 2020 Oct 7.
4
Fat and Hidden Liver Cancer.
Clin Liver Dis (Hoboken). 2021 Feb 28;17(2):49-52. doi: 10.1002/cld.1011. eCollection 2021 Feb.
5
Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse.
Liver Int. 2021 May;41(5):1012-1019. doi: 10.1111/liv.14805. Epub 2021 Feb 20.
6
Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
Front Endocrinol (Lausanne). 2020 Dec 23;11:592373. doi: 10.3389/fendo.2020.592373. eCollection 2020.
7
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
J Hepatol. 2021 May;74(5):1109-1116. doi: 10.1016/j.jhep.2020.11.050. Epub 2020 Dec 9.
8
Immunological mechanisms and therapeutic targets of fatty liver diseases.
Cell Mol Immunol. 2021 Jan;18(1):73-91. doi: 10.1038/s41423-020-00579-3. Epub 2020 Dec 2.
10
Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
Hepatology. 2021 Feb;73(2):548-559. doi: 10.1002/hep.31608. Epub 2021 Feb 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验